The Bristol-Myers Squibb Company is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the worlds largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.
Company profile
Ticker
BMY
Exchange
Website
CEO
Giovanni Caforio
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
1096271 BC ULC • 345 Park LLC • 9643435 Canada Inc. • Abraxis BioScience Australia Pty Ltd. • Abraxis BioScience International Holding Company, Inc. • Abraxis BioScience Puerto Rico, LLC • Abraxis BioScience, Inc. • Abraxis BioScience, LLC • AbVitro LLC • Acetylon Pharmaceuticals, Inc. ...
IRS number
220790350
BMY stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
18 Mar 24
PRE 14A
Preliminary proxy
18 Mar 24
8-K
Strengthening Neuroscience Portfolio
18 Mar 24
SC TO-T/A
Third party tender offer statement (amended)
23 Feb 24
8-K
Other Events
22 Feb 24
424B5
Prospectus supplement for primary offering
16 Feb 24
SC TO-T/A
Third party tender offer statement (amended)
16 Feb 24
8-K
Departure of Directors or Certain Officers
15 Feb 24
FWP
Free writing prospectus
14 Feb 24
8-K
Bristol Myers Squibb Recommends Stockholders Reject “Mini-Tender” Offer by Tutanota LLC
14 Feb 24
Transcripts
BMY
Earnings call transcript
2023 Q4
2 Feb 24
BMY
Earnings call transcript
2023 Q3
26 Oct 23
BMY
Earnings call transcript
2023 Q2
27 Jul 23
BMY
Earnings call transcript
2023 Q1
27 Apr 23
BMY
Earnings call transcript
2022 Q4
2 Feb 23
BMY
Earnings call transcript
2022 Q3
26 Oct 22
BMY
Earnings call transcript
2022 Q2
27 Jul 22
BMY
Earnings call transcript
2022 Q1
29 Apr 22
BMY
Earnings call transcript
2021 Q4
4 Feb 22
BMY
Earnings call transcript
2021 Q3
27 Oct 21
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 7.57 bn | 7.57 bn | 7.57 bn | 7.57 bn | 7.57 bn | 7.57 bn |
Cash burn (monthly) | 285.67 mm | 32.42 mm | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 1.61 bn | 182.60 mm | n/a | n/a | n/a | n/a |
Cash remaining | 5.96 bn | 7.39 bn | n/a | n/a | n/a | n/a |
Runway (months of cash) | 20.9 | 227.8 | n/a | n/a | n/a | n/a |
Institutional ownership, Q4 2023
53.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1959 |
Opened positions | 190 |
Closed positions | 560 |
Increased positions | 540 |
Reduced positions | 1034 |
13F shares | Current |
---|---|
Total value | 52.73 tn |
Total shares | 1.09 bn |
Total puts | 7.41 mm |
Total calls | 11.59 mm |
Total put/call ratio | 0.6 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 198.16 mm | $10.17 tn |
JPM JPMorgan Chase & Co. | 90.05 mm | $4.62 tn |
STT State Street | 89.45 mm | $4.59 tn |
Capital International Investors | 61.53 mm | $3.16 tn |
FMR | 42.61 mm | $2.19 tn |
MS Morgan Stanley | 29.38 mm | $1.51 tn |
NTRS Northern Trust | 24.01 mm | $1.23 tn |
Primecap Management | 23.53 mm | $1.21 tn |
LGEN Legal & General | 19.81 mm | $1.02 tn |
BK Bank Of New York Mellon | 17.02 mm | $873.41 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
10 Mar 24 | Gregory Scott Meyers | Performance Shares Common Stock, $0.10 par value | Grant | Acquire A | No | No | 0 | 29,025 | 0.00 | 29,025 |
10 Mar 24 | Gregory Scott Meyers | Market Share Units Common Stock, $0.10 par value | Grant | Acquire A | No | No | 0 | 19,350 | 0.00 | 19,350 |
10 Mar 24 | Gregory Scott Meyers | Market Share Units Common Stock, $0.10 par value | Other | Dispose J | No | No | 0 | 3,293 | 0.00 | 9,880 |
10 Mar 24 | Gregory Scott Meyers | Market Share Units Common Stock, $0.10 par value | Other | Dispose J | No | No | 0 | 2,836 | 0.00 | 5,675 |
10 Mar 24 | Benjamin Hickey | Performance Shares Common Stock, $0.10 par value | Grant | Acquire A | No | No | 0 | 5,805 | 0.00 | 5,805 |
10 Mar 24 | Benjamin Hickey | Market Share Units Common Stock, $0.10 par value | Grant | Acquire A | No | No | 0 | 3,870 | 0.00 | 3,870 |
10 Mar 24 | Karin Shanahan | Performance Shares Common Stock, $0.10 par value | Grant | Acquire A | No | No | 0 | 34,830 | 0.00 | 34,830 |
10 Mar 24 | Karin Shanahan | Market Share Units Common Stock, $0.10 par value | Grant | Acquire A | No | No | 0 | 23,220 | 0.00 | 23,220 |
10 Mar 24 | Karin Shanahan | Market Share Units Common Stock, $0.10 par value | Other | Dispose J | No | No | 0 | 3,293 | 0.00 | 9,880 |
10 Mar 24 | Karin Shanahan | Market Share Units Common Stock, $0.10 par value | Other | Dispose J | No | No | 0 | 2,447 | 0.00 | 4,895 |
News
FDA Adcomm Favors Expanded Use Of Johnson & Johnson, Bristol Myers' CAR-T Therapies For Type Of Blood Cancer
18 Mar 24
Reported Saturday, FDA Advisory Committee Votes In Favor Of Bristol Myers Squibb's And 2seventy Bio's Abecma For Triple-Class Exposed Multiple Myeloma In Earlier Lines Of Therapy
18 Mar 24
Bristol Myers' Breyanzi Scores Second FDA Approval For Blood Cancers Therapy
15 Mar 24
What's Going On With Cancer Focused-Geron Stock On Friday?
15 Mar 24
Bristol Myers Squibb's Breyanzi® Approved By U.S. FDA As The First And Only CAR T Cell Therapy For Adults With Relapsed Or Refractory Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma
15 Mar 24
Press releases
Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio
18 Mar 24
FDA Advisory Committee Votes in Favor of Bristol Myers Squibb's and 2seventy bio's Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
15 Mar 24
U.S. FDA Approves Bristol Myers Squibb's Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
14 Mar 24
Bristol Myers Squibb to Report Results for First Quarter 2024 on April 25, 2024
11 Mar 24
U.S. Food and Drug Administration Approves Opdivo® (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
7 Mar 24